27

Satellite Symposia

Saturday | Sunday | Monday | Tuesday

Company-sponsored Satellite Symposia take place at lunchtime as well as in the morning and in the evening. They provide cutting-edge information on interventional equipment and techniques.


Satellite Symposia Programme
as per August 8, 2017


Saturday, September 16, 2017   TOP
 

  13:00-14:00, Auditorium 3
  Bayer AG
SY 401
 
Extending survival in unresectable HCC: how can I optimize sequencing in my clinic?
   
  Moderator: M. Seidensticker (Munich/DE)
   
401.1
 
401.2
 
401.3
 
401.4
Evidence for locoregional therapy: what have we learned?
M. Seidensticker (Munich/DE)
Systemic therapy and sequencing in uHCC: what do we know?
M. Peck-Radosavljevic (Klagenfurt/AT)
uHCC in practice: what would you do?
F. Piscaglia (Bologna/IT)
Q&A
   
   
  13:00-14:00, Auditorium 15
  Biotronik AG
SY 402 Minimal is optimal in SFA therapy, reducing metal burden
   
  Moderator: J.C. van den Berg (Lugano/CH)
   
402.1
 
 
402.2
 
402.3
 
 
402.4
 
 
402.5
 
 
BIOFLEX COF – the effect of stent radial force: Results of preclinical study and interim results for RCT
M.A. Funovics (Vienna/AT)
BIOFLEX PEACE – Pulsar-18 all-comers registry: 12-month results for the full cohort
C. Nolte-Ernsting (Mühlheim/DE)
BIOLUX P-III – Passeo-18 Lux all-comers registry: 12-month results for the full cohort of 700+ subjects
G. Tepe (Rosenheim/DE)
BIOLUX 4EVER: Combining Passeo-18 Lux DCB and Pulsar-18 BMS: 12-month results of full cohort
K. Deloose (Dendermonde/BE)
REACT: REsponse Adapted Combination Therapy: Concept and study outline for
an RCT
R. Langhoff (Berlin/DE)
   
   
  13:00-14:00, Auditorium 12
  Philips
SY 403 The pivotal role of advanced image guidance in interventional oncology
   
  Moderators: A. Gangi (Strasbourg/FR), E. Kim (New York, NY/US),
B.J. Wood (Bethesda, MD/US)
   
403.1
 
 
403.2
 
 
403.3
 
 
Cone-beam CT and EmboGuide in the treatment of primary and metastatic
liver malignancies
G. Maleux (Leuven/BE)
Advances in therapy planning and image guidance for lung ablation in the
interventional lab
J. Palussière (Bordeaux/FR)
Cone-beam CT navigation in interventional oncology: established evidence
and future developments
N. Abi-Jaoudeh (Irvine, CA/US)
   
   
  16:15-16:35, Room 20
  Biotronik AG
SY 608 Minimal is optimal in SFA therapy, reducing access complications
   
  Moderator: K. Deloose (Dendermonde/BE)
   
608.1
 
608.2
 
608.3
 
608.4
 
 
Ambulatory intervention: Concept & rationale to consider ambulatory intervention
K. Deloose (Dendermonde/BE)
Clinical evidence so far: Retrospective data – a Swiss experience
J.C. van den Berg (Lugano/CH)
Clinical evidence so far: Retrospective data – a French experience
O. Regnard (Trelaze/FR)
BIO4AMB randomised controlled trial – outline: A 4F vs. 6F+VCD study of ambulatory treatment for SFA disease
E. Steinmetz (Dijon/FR)
   
   
  16:15-16:35, Auditorium 12
  Merit Medical
SY 609 HEPDOX & HEPIRI: optimise your TACE in HCC and CRC mets to the liver!
   
  Moderator: S. Pluntke (Essen/DE)
   
609.1
 
609.2
 
HepaSphere™ TACE, a Vancouver perspective
D. Klass (Vancouver, BC/CA)
TACE with HepaSphere™ drug-eluting microspheres in CRC mets to the liver
K. Malagari (Athens/GR)
   
   
   
Sunday, September 17, 2017   TOP
   
  08:00-08:20, Room 20
  Veryan Medical
SY 801 BioMimics 3D, the swirling flow stent: what makes it so different?
   
  Moderator: P.A. Gaines (Sheffield/UK)
   
801.1
 
What is swirling flow and why is it so important to femoropopliteal outcomes?
G. Tepe (Rosenheim/DE)
801.2
 
Latest clinical experience with BioMimics 3D
M. Lichtenberg (Arnsberg/DE)
801.3

 
Swirling flow: producing better results in both primary stenting and in
combination with DCB
P.A. Gaines (Sheffield/UK) 
   
   
  11:30-12:30, Auditorium 1
  Boston Scientific
SY 1102 Strategies for SFA intervention: evidence, controversy and debate
   
  Moderator: M. Brodmann (Graz/AT)
   
1102.1
 
1102.2
 
1102.3
 
1102.4
 
1102.5
12m data from Ranger all-comers registry
M. Lichtenberg (Arnsberg/DE)
My go to strategy: drug-coated balloon
G. Tepe (Rosenheim/DE)
My go to strategy: drug-eluting stent
Y. Gouëffic (Nantes/FR)
My go to strategy: atherectomy and drug elution
K.N. Katsanos (Patras/GR)
Moderated debate and challenge
   
   
  11:30-12:30, Auditorium 3
  Medtronic
SY 1103
 
Optimizing treatment outcomes in complex vascular disease with DCB combination therapy
   
  Moderators: F. Fanelli (Florence/IT), A. Holden (Auckland/NZ)
   
1103.1
 
1103.2
 
 
1103.3
 
1103.4
 
1103.5
 
Opening remarks & introduction
F. Fanelli (Florence/IT)
IN.PACT DCB is changing the first line therapy for the treatment of complex SFA
disease
J.C. van den Berg (Lugano/CH)
Vessel prep technology: when DCB alone is not enough
P. Krishnan (New York, NY/US)
Prolong dialysis access with combination of IN.PACT DCB and Fortrex HP Balloon
M. Treitl (Munich/DE)
Take home messages & closing remarks
A. Holden (Auckland/NZ)
   
   
  11:30-12:30, Auditorium 2
  Sirtex Medical Europe GmbH
SY 1104
 
SIR-Spheres Y-90 resin microspheres – providing the evidence in interventional oncology
   
  Moderators: B. Gebauer (Berlin/DE), R. Sharma (London/UK)
   
1104.1
 
1104.2
 
1104.3
 
1104.4
Latest evidence on Y-90 resin microspheres in mCRC
D. Arnold (Hamburg/DE)
Latest evidence on Y-90 resin microspheres in HCC
V. Vilgrain (Clichy/FR)
Dosimetry made easy
A. Martínez de la Cuesta (Pamplona/ES)
Panel discussion: Implications of the new data for clinical practice
   
   
  13:00-14:00, Auditorium 15
  BTG
SY 1201 Setting new standards in thrombolysis
   
  Moderator: M. Treitl (Munich/DE)
   
1201.1
 
 
1201.2
 
 
1201.3
 
 
The ACCESS PTS study: reducing post-thrombotic syndrome with EKOS™ in the treatment of chronic DVT patients
M.J. Garcia (Wilmington, DE/US)
The OPTALYSE PE trial: reducing thrombolytic dose and treatment times with EKOS™ in the treatment of pulmonary embolism patients
K.M. Sterling (Alexandria, VA/US)
The Munich experience: reducing lab time with EKOS™ in the treatment of acute DVT and PAO patients
M. Treitl (Munich/DE)
   
   
  13:00-14:00, Auditorium 2
  Medtronic
SY 1202 Breakthrough technologies in thermal ablation
   
  Moderator: G. Carrafiello (Milan/IT)
   
1202.1

 
Liver ablation: outcome analysis of percutaneous and intraoperative
approaches with different liver conditions
F. De Cobelli (Milan/IT)
1202.2 
 
Lung ablation: 100+ patients treated with Emprint ablation system
T.J. Vogl (Frankfurt/DE)
1202.3
 
Kidney ablation: 150+ patients treated with Emprint ablation system
A. Magnusson (Uppsala/SE)
1202.4 
 
Emprint spherical ablations: what is the secret?
J. Case (Boulder, CO/US)
   
   
  13:00-14:00, Auditorium 1
  Terumo Europe
SY 1203 Critical limb ischaemia – All you need to know in 60’
   
  Moderator: M.G. Manzi (Abano Terme/IT)
   
1203.1
 
1203.2
 
1203.3
 
1203.4
 
1203.5
 
1203.6
 
Objective of the meeting
M.G. Manzi (Abano Terme/IT)
CLI – Where we are today
M.G. Manzi (Abano Terme/IT)
CLI – Patient centric approach – Multidisciplinary Team
S.T. Rashid (Manchester/UK)
Debate on endovascular intervention strategies – Case discussions
K. Deloose (Dendermonde/BE), M. Palena (Abano Terme/IT)
Good access leads to good closure
S. Müller-Hülsbeck (Flensburg/DE)
Conclusions
M.G. Manzi (Abano Terme/IT)
   
   
  14:30-15:30, Auditorium 15
  Medtronic
SY 1303
 
Evidence-based treatment decision and innovation in musculoskeletal
procedures
   
  Moderator: D.P. Beall (Oklahoma City, OK/US)
   
1303.1
 
Is sagittal alignment worth pursuing in VCF treatments?
P. Maxy (Tolochenaz/CH)
1303.2
 
VCF mortality risks and the latest clinical evidence on balloon kyphoplasty
D.P. Beall (Oklahoma City, OK/US)
1303.3

 
Bone ablation: take the lead and offer an impactful treatment for your
oncologic patients!
R.L. Cazzato (Strasbourg/FR)
   
   
  14:30-15:30, Auditorium 10
  Straub Medical AG
SY 1304
 
How to successfully treat venous occlusions: from creating a venous service to approaching challenging cases
   
  Moderator: M. Lichtenberg (Arnsberg/DE)
   
1304.1
 
1304.2
 
1304.3  
 
1304.4
 
1304.5
   
 
Setting up a deep venous service in your hospital
G.J. O'Sullivan (Galway/IE)
Current evidence on venous thrombectomy post ATTRACT
M. Lichtenberg (Arnsberg/DE)
Aspirex®S – a versatile tool for venous thrombectomy
T. Heller (Rostock/DE)
Haemodialysis vascular access salvage with Rotarex mechanical debulking device
C.R. Riguetti Pinto (Rio de Janeiro/BR)
Percutaneous mechanical thrombectomy for acute symptomatic iliofemoral deep vein thrombosis using the Aspirex®S catheter
R. Loffroy (Dijon/FR)
   
   
  16:15-16:35, Auditorium 12
  Merit Medical
SY 1409
 
The Surfacer® Inside-Out® access catheter system: to restore and preserve access in chronically occluded veins
   
1409.1 G. Sengölge (Vienna/AT)
   
   
  16:15-16:55, Auditorium 11
  Medtronic
SY 1410
 
A time to open, a time to close: discussion on deep venous stenting to embolisation therapies
   
  Moderator: M. Treitl (Munich/DE)
   
1410.1
 
1410.2
 
Deep venous stenting: the why and the how
H. Jalaie (Aachen/DE)
Ovarian vein embolisation with Onyx® for patients with pelvic congestion syndrome
C. Marcelin (Bordeaux/FR)
   
   
  16:45-17:05, Auditorium 12
  Spectranetics
SY 1411 Stellarex drug-coated-balloon: new evidence and new perspectives
   
  Moderator: G. Tepe (Rosenheim/DE)
   
1411.1
 
 
1411.2
 
New evidence from the ILLUMENATE clinical programme: 2-year results from the European randomised trial
H. Schröder (Berlin/DE)
Role of plaque scoring before DCB: mechanism of action and case review
S. Bays (Aylesbury/UK)
   
   
   
Monday, September 18, 2017   TOP
   
  08:00-08:20, Room 20
  B. Braun Melsungen AG
SY 1601 Spot stenting: it’s time to undress the full metal jacket
   
  Moderator: G. Tepe (Rosenheim/DE)
   
1601.1
 
Long stents vs. short stents
M.G. Manzi (Abano Terme/IT)
1601.2
 
Spot stenting with VascuFlex® Multi-LOC
R. Langhoff (Berlin/DE)
1601.3
 
Challenging case: SFA total occlusion
P. Goverde (Antwerp/BE)
1601.4  Discussion
   
   
  11:30-12:30, Auditorium 1
  Cook Medical
SY 1902 Patient first: leave the right thing behind
   
  Moderator: M.D. Dake (Stanford, CA/US)
   
1902.1
 
1902.2
 
1902.3
 
1902.4
 
1902.5
 
1902.6
 
1902.7
 
1902.8
 
Introduction
M.D. Dake (Stanford, CA/US)
Why and how to prepare the vessel?
F. Fanelli (Florence/IT)
Panel discussion: Advance Enforcer 35 + Zilver PTX case discussion – recorded case from Rome, Italy
New results on DCB versus DES – what we know from the latest research
R. Virmani (Gaithersburg, MD/US)
ZILVERPASS: Zilver PTX versus bypass
K. Deloose (Dendermonde/BE)
Panel discussion: Recorded case experience with the new 140 mm Zilver PTX from Dendermonde, Belgium
The importance of scientific evidence
J.A. Kaufman (Portland, OR/US)
Summary
M.D. Dake (Stanford, CA/US)
   
   
  11:30-12:30, Auditorium 3
  Penumbra
SY 1903 Penumbra embolisation and thrombectomy advanced technology
   
  Moderators: T. Bisdas (Münster/DE), B. Huasen (Preston/UK)
   
1903.1
 
1903.2
 
1903.3
 
My experience in arterial occlusions with the Indigo system
T. Bisdas (Münster/DE)
Penumbra Indigo system for fistula and venous thrombosis
B. Huasen (Preston/UK)
How Ruby Coil and POD system have changed my way in embolisation therapies
H. Mehrzad (Birmingham/UK)
   
   
  11:30-12:30, Auditorium 2
  Terumo Europe
SY 1904 Pushing boundaries: adding Q to SIRT
   
  Moderators: T.F. Jakobs (Munich/DE), M. Peeters (Edegem/BE)
   
1904.1
 
1904.2
 
1904.3
 
The potential for SIRT to improve treatment for primary and secondary liver cancers
R. Sharma (London/UK)
Taking SIRT to the next level
M.G.E.H. Lam (Utrecht/NL)
From years of research to successful patient management
R.-T. Hoffmann (Dresden/DE)
   
   
  13:00-14:00, Auditorium 1
  Boston Scientific
SY 2001 Deep venous interventions. Current state, future directions
   
  Moderator: M.J. Lee (Dublin/IE)
   
2001.1
 
2001.2
 
2001.3
 
2001.4
 
2001.5
 
2001.6
Opening and learning objectives
M.J. Lee (Dublin/IE)
A European view on ATTRACT trial
to be announced
Keeping deep veins open: imaging, intervention and surveillance
R. de Graaf (Maastricht/NL)
Post thrombotic syndrome: pathology and sequalae
M. Lugli (Modena/IT)
Chronic venous disease: healthcare burden and patient management
G.J. O’Sullivan (Galway/IE)
Moderated discussion: where to next?
   
   
  13:00-14:00, Auditorium 2
  Guerbet
SY 2002 Liver cancer & lymphatic disorders, therapy evolutions for patient benefit
   
  Moderator: V. Vilgrain (Clichy/FR)
   
2002.1
 
2002.2
 
2002.3
 
cTACE, technique standardisation & safety
M.C. Soulen (Philadelphia, PA/US)
HCC treatment, efficiency of bridging & downstaging combined therapies
V. Vilgrain (Clichy/FR)
Technical & clinical considerations of lymphatic disorders treatment
M. Itkin (Philadelphia, PA/US)
   
   
  13:00-14:00, Auditorium 15
  Toshiba Medical
SY 2003 Infinix-i 4D CT: the future of today in interventional radiology
   
  Moderator: Y. Arai (Tokyo/JP)
   
2003.1
 
Interventional oncology beyond liver interventions
E. de Kerviler (Paris/FR)
2003.2
 
Is 3D information enough for sophisticated IRs?
Y. Arai (Tokyo/JP)
2003.3
 
Infinix-i 4D CT – new milestone in liver interventional oncology
B. Guiu (Montpellier/FR)
   
   
  13:30-14:00, Auditorium 3
  Endologix
SY 2004
 
Polymer sealing for AAA: why we need to consider an alternative to
traditional EVAR
   
  Moderator: A. Holden (Auckland/NZ)
   
2004.1
 
EVAR: what we’ve learned after 25 years
M. Reijnen (Arnhem/NL)
2004.2
 
EVAS: the clinical and biological advantages of active sac management
A. Holden (Auckland/NZ)
2004.3
 
Raising the standard for EVAR in women
M. Storck (Karlsruhe/DE)
   
   
  14:30-15:30, Auditorium 15
  BTG
SY 2105
 
See more. Reach further. Treat smarter. Taking tumour ablation to the
next level with Galil cryoablation
   
  Moderator: D.J. Breen (Southampton/UK)
   
2105.1
 
Renal cryoablation: the new standard of care
O. Graumann (Odense/DK)
2105.2
 
Cryoablation of bone metastases: first choice for durable palliative treatment
J. Garnon (Strasbourg/FR)
2105.3
 
Lung tumour cryoablation: transient or viable treatment option?
L. Tselikas (Villejuif/FR)
   
   
  16:15-16:35, Auditorium 12
  Merit Medical
SY 2209 RF ablation in the spine: innovation and clinical evidence
   
2209.1 J.W. Jennings (St. Louis, MO/US)
   
   
  16:45-17:05, Auditorium 12
  TVA Medical
SY 2210
 
Pioneering a new path for dialysis access creation with the everlinQ endoAVF System
   
  Moderator: R.-T. Hoffmann (Dresden/DE)
   
2210.1
2210.2
T.M. Steinke (Duesseldorf/DE)
R.G. Jones (Birmingham/UK)
   
   
  17:30-18:00, Auditorium 12
  Gore & Associates
SY 2309
 
Introducing GORE® VIATORR® TIPS Endoprosthesis with controlled expansion: evidence-based discussion
   
  Moderator: P. Goffette (Brussels/BE)
   
2309.1
 
2309.2
 
 
The concept of cTIPS with controlled expansion. How does it work?
G. Maleux (Leuven/BE)
A review of the early results of cTIPS with controlled expansion to treat refractory
ascites
F. Nevens (Leuven/BE)
   
   
   
Tuesday, September 19, 2017   TOP
   
  13:00-14:00, Auditorium 15
  BTG
SY 2801 DC Bead LUMI™: beyond seeing
   
  Moderator: T.F. Jakobs (Munich/DE)
   
2801.1
 
2801.2
 
2801.3
 
2801.4
 
Initial data on the utility of DC Bead LUMI™ beyond visibility in liver malignancies
C. Aliberti (Lagosanto/IT), R. Carandina (Padova/IT)
Early treatments with DC Bead LUMI™: the Pisa experience
I. Bargellini (Pisa/IT)
Early treatments with DC Bead LUMI™: the Milan experience
C. Spreafico (Milan/IT)
The “Hug Effect”: providing confidence in your safety margins with enhanced RFA
R. Iezzi (Rome/IT)
   
   
  13:00-14:00, Auditorium 3
  Medtronic
SY 2802 Acute ischaemic stroke treatment: state-of-the-art in 2017
   
2802.1
 
Who will treat acute ischaemic stroke patients in the future?
J. Fiehler (Hamburg/DE)
2802.2
 
An experienced center Royal Stoke Hospital
S. Nayak (Stoke-on-Trent/UK)
   
   
  13:00-14:00, Auditorium 2
  Siemens Healthineers
SY 2803
 
From routine cases to demanding interventions – pushing boundaries with smart imaging approaches
   
  Moderator: F.C. Carnevale (São Paulo/BR)
   
2803.1
 
2803.2
 
2803.3
 
Best practices to reduce radiation in complex interventions
G.M. Richter (Stuttgart/DE)
CBCT as a mandatory tool for PAE: guidance and target evaluation
M.R. Sapoval (Paris/FR)
Robotic imaging in the comprehensive spectrum of interventions in a military hospital
S. Waldeck (Koblenz/DE)
   
   
  14:30-15:30, Auditorium 15
  PharmaCept GmbH
SY 2905 New clinical and experimental outcomes of DSM-TACE
   
  Moderators: R. Iezzi (Rome/IT), T.J. Vogl (Frankfurt/DE)
   
2905.1
 
 
2905.2
 
 
 
2905.3
 
2905.4
 
 
2905.5
 
DSM-TACE: a powerful treatment option for patients with recurrent CCC after
liver resection
C. Kuhl (Aachen/DE)
HAI of irinotecan leads to higher tumour tissue concentration of SN38
when combined with EmboCept® S in preclinical model for colorectal liver
metastases
A. Kauffels-Sprenger (Göttingen/DE)
DSM-TACE for locally advanced HCC
T. Albrecht (Berlin/DE)
DSM-TACE in intermediate/advanced HCC patients dismissing or ineligible for
multikinase-inhibitor chemotherapy treatment (Sorafenib)
R. Iezzi (Rome/IT)
DSM-TACE vs. cTACE: study results of FAST I – II in HCC and CRC
T.J. Vogl (Frankfurt/DE)